$1.47
2.65% yesterday
Nasdaq, Jan 06, 10:02 pm CET
ISIN
US00972D1054
Symbol
AKBA

Akebia Therapeutics, Inc. Stock price

$1.47
-0.15 9.26% 1M
-2.16 59.50% 6M
-0.14 8.70% YTD
-0.40 21.39% 1Y
+0.83 128.90% 3Y
-1.52 50.84% 5Y
-8.13 84.69% 10Y
-25.23 94.49% 20Y
Nasdaq, Closing price Tue, Jan 06 2026
-0.04 2.65%
ISIN
US00972D1054
Symbol
AKBA
Industry

Key metrics

Basic
Market capitalization
$400.7m
Enterprise Value
$426.2m
Net debt
$25.5m
Cash
$166.4m
Shares outstanding
265.2m
Valuation (TTM | estimate)
P/E
negative | 33.7
P/S
1.8 | 1.6
EV/Sales
1.9 | 1.7
EV/FCF
13.2
P/B
9.6
Financial Health
Equity Ratio
-22.3%
Return on Equity
141.1%
ROCE
8.7%
ROIC
11.4%
Debt/Equity
4.6
Financials (TTM | estimate)
Revenue
$225.1m | $244.1m
EBITDA
$29.2m | -
EBIT
$20.1m | $35.5m
Net Income
$-15.9m | $11.9m
Free Cash Flow
$32.2m
Growth (TTM | estimate)
Revenue
32.5% | 52.4%
EBITDA
627.2% | -
EBIT
162.9% | 176.9%
Net Income
65.4% | 117.1%
Free Cash Flow
183.5%
Margin (TTM | estimate)
Gross
82.5%
EBITDA
13.0% | -
EBIT
9.0%
Net
-7.1% | 4.9%
Free Cash Flow
14.3%
More
EPS
$-0.1
FCF per Share
$0.1
Short interest
13.2%
Employees
181
Rev per Employee
$880.0k
Show more

Is Akebia Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,084 stocks worldwide.

Akebia Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Akebia Therapeutics, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Akebia Therapeutics, Inc. forecast:

Buy
91%
Hold
9%

Financial data from Akebia Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
225 225
32% 32%
100%
- Direct Costs 39 39
52% 52%
17%
186 186
29% 29%
83%
- Selling and Administrative Expenses 109 109
5% 5%
48%
- Research and Development Expense 48 48
33% 33%
21%
29 29
627% 627%
13%
- Depreciation and Amortization 9.01 9.01
75% 75%
4%
EBIT (Operating Income) EBIT 20 20
163% 163%
9%
Net Profit -16 -16
65% 65%
-7%

In millions USD.

Don't miss a Thing! We will send you all news about Akebia Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Akebia Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
about 11 hours ago
CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the first patient has been dosed in a Phase 2 clinical trial of praliciguat, an oral, once-daily soluble guanylate cyclase (sGC) stimulator being evaluated for the treatment of...
Neutral
GlobeNewsWire
one day ago
CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 197,900 shares of Akebia's common stock on December 31, 2025. The options were granted as an inducement material to the employee...
Neutral
GlobeNewsWire
about one month ago
CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 22,576 shares of Akebia's common stock on November 28, 2025.
More Akebia Therapeutics, Inc. News

Company Profile

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Head office United States
CEO John Butler
Employees 181
Founded 2007
Website akebia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today